Drug Trial Radar · NCT05704361
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
119
Planned (sponsor's estimate)
Start
Aug 11, 2021
Primary completion
Jul 8, 2027
Study completion Jul 8, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3), and multiple-ascending SC doses following a single IV dose (Part 4) of RO7121932 in participants with multiple sclerosis (MS). Only Parts 1 and 2 of the study will be conducted in the United States, whereas Parts 1, 2, 3, and 4 will be conducted in all other participating countries outside the United States.
Conditions
- Multiple Sclerosis
Interventions
RO7121932 IVDrug
Participants will receive RO7121932, as an IV infusion, per the schedule specified in the treatment arms.
RO7121932 SCDrug
Participants will receive RO7121932, as SC injection, per the schedule specified in the treatment arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1, 2, 3, and 4: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) With Severity of AEs Measured According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5 (NCI CTCAE V5)Time frame: Day 1 to Day 169 for Part 1 and Part 2; Day 1 to Day 197 for Part 3; Day 1 to Day 253 for Part 4
- Parts 1, 2, 3, and 4: Change From Baseline in Suicide Risk as Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Day 1 to Day 169 for Part 1 and Part 2; Day 1 to Day 197 for Part 3; Day 1 to Day 253 for Part 4
- Parts 2 and 3: Percentage of Participants With Local Pain at the Site of Injection Assessed Using the Visual Analog Scale (VAS)Time frame: Day 1, 2, 5, 8 for Part 2; Day 1, 2, 5, 8, 15, 22, 29, 36 for Part 3
- Parts 2 and 3: Percentage of Participants With Local Injection-site Reaction Using Local Injection-site Symptom Assessment (LISSA)Time frame: Day 1,2, 5, 8 for Part 2; Day 1, 2, 5, 8, 15, 22, 29, 36 for Part 3
- Part 4: Percentage of Participants With Local Injection-site ReactionsTime frame: Day 1 to Day 253
Locations
26 sites in 12 countries. Site status is shown where the registry gives one.
Stanford University Medical Center
Stanford, California
Yale University Multiple Sclerosis Center
New Haven, Connecticut
Cliniques Universitaires St-Luc
Brussels, Belgium
UZ Gent
Ghent, Belgium
Montreal Neurological Institute and Hospital
Montreal, Quebec, Canada
Universitätsklinikum "Carl Gustav Carus"
Dresden, Germany
Universitätsmedizin Göttingen Georg-August-Universität
Göttingen, Germany
Klinikum rechts der Isar der TU Muenchen
München, Germany
Universitätsklinikum Münster Klinik u. Poliklinik f. Neurologie
Münster, Germany
Universitätsklinikum Tübingen, Zentrum für Neurologie
Tübingen, Germany
Universitätsklinikum Ulm
Ulm, Germany
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel
IRCCS Ospedale San Raffaele
Milan, Lombardy, Italy
Fond. Istituto Neurologico C.Besta
Milan, Lombardy, Italy
ARENSIA Exploratory Medicine Phase I, PMSI Republican Clinical Hospital
Chisinau, Moldova
Regionalny Szpital Specjalistyczny im. W. Bieganskiego
Grudzi?dz, Poland
MedPolonia
Poznan, Poland
Osrodek Badan Klinicznych Euromedis
Szczecin, Poland
SPSK nr 1
Zabrze, Poland
Hospital de Braga
Braga, Portugal
Hospital Santo Antonio dos Capuchos
Lisbon, Portugal
Centro Hospitalar Entre o Douro e Vouga E.P.E. - Hospital de São Sebastião
Santa Maria da Feira, Portugal
ARENSIA Exploratory Medicine SRL - Bucharest (Monza Medical Center)
Bucharest, Romania
ARENSIA Exploratory Medicine, County Emergency Hospital
Cluj-Napoca, Romania
University Clinical Center of Serbia
Belgrade, Serbia
Hospital Universitari Vall dHebron (CEMCAT)
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.